Management of hepatitis C virus infection in HIV/HCV co-infected patients: Clinical review

Table 2 Trials of anti-HCV treatment in HIV patients

Author (yr)	Country	n	Schedule	Duration	Overall response (%)		GT-2/3		GT-1/4
					ETR	SVR	ETR	SVR	ETR	SVR
Pérez-Olmeda et al[39] (2003)	Spain	68	PEG-IFN 150 μg/wk × 12 wk, then 100 μg/wk + RBV 400 mg bid	6 mo for GT-1/4 and 12 mo for GT-3	30.3	24.2	811	52.3	30.3	24.2
Cargnel et al[40] (2005)	Italy Multi Center	135	PEG-IFN 1.5 μg/kg per week + RBV 400 bid	48 wk	28.9	21.7	43.7	34.4	18.7	9.4
			PEG-IFN 1.5 μg/kg per week		16.7	9.1	16.2	10.8	14.7	8.8
Bräu et al[41] (2004)	United States	107	IFN α-2b 3 mu tiw + RBV 800 mg /d vs	48 wk	18.9	11.3	50	41.7	10	2.5
			IFN α 2b 3 mu tiw + placebo × 16 wk, then RBV 800 mg/d		7.4	5.6
Laguno et al[42] (2004)	Spain	95	IFN α 2b 3 mu tiw + RBV 800-1200 mg/d vs	48 wk for GT-¼ and 24 wk for HT-2/3	301	211	67	47	11	7
			PEG-IFN 100-150 μg/wk + RBV 800-1200 mg/d		52	44	68	53	41	38
Myers et al[43] (2004)	Canada	32	PEG-IFN α 2b (1.5 μg/kg per week) + weight based RBV (1000 mg for 75 kg or less or 1200 mg for > 75 kg) in IFN non responders	48 wk	19	16		29		9
Chung et al[44] (2004) ACTG	United States	133	PEG-IFN α 2a 180 μg/wk + RBV (400 mg/d × 4 wk- 600 mg/d × 4 wk - 1000 mg/d vs	48 wk	411	271	801	731	331	29
			IFN α 2a 6 mu tiw × 12 wk, then 3 mu tiw +RBV as above		12	12	33	33	6	6
Moreno et al[45] (2004)	Spain	35	PEG-IFN 50 μg/wk + RBV 800 mg/d	48 wk		31		70		25
Torriani et al[46] (2004)	APRICOT	868	PEG-IFN α 2a 180 μg/wk + RBV 800 mg/d vs	48 wk	47	401	64	621	38	29
			PEG-IFN α 2a + Placebo vs		31	20	57	36	21	14
			IFN α 2a 3 mu tiw + RBV		14	12	27	20	8	7
Carrat et al[47] (2004) RIBAVIC	France Multi Center	412	PEG-IFN α 2b 1.5 μg/kg per week + RBV 800 mg/d vs	48 wk	351	271	50	43.7	25.6	16.81
			IFN α 2b 3 mu tiw + RBV 800 mg/d		21	20	47.4	43.4	6.2	6.2
Khalili et al[48] (2005)	United States	154	PEG-IFN α 2a 180 μg/wk	48 wk	55	35	NA
			PEG-IFN + Placebo		3	0
			PEG-IFN + RBV 800 mg/d		11	5
Hopkins et al[49] (2006)	United Kingdom	45	PEG-IFN α 2b 1.5 μg/kg per week + RBV (1000-1200 mg/d)	24 wk for GT- 2/3 and 48 wk for GT-1	62	53	82	751	25	19
Moreno et al[50] (2006)	Spain	70 (HCV)	PEG-IFN α 2b 1.5 μg/kg per week + RBV 10.6 mg/kg per day	48 wk	46	371	All patients had GT-1 or 4 infection and the overall ETR and SVR were 39 and 30% respectively
		36 (HCV +HIV)			25	171
Santin et al[51] (2006)	Spain Multi Center	60	PEG-IFN α 2b 80-150 μg/wk + RBV 800-1200 mg/d	24 wk for GT 2/3 and 48 wk for GT ¼	33	27	53	42	24	201
Voigt et al[52] (2006)	Germany Multi Center	122	PEG-IFN α 2b 1.5 μg/kg per week + RBV 800 mg/d	24 wk for GT 2/3 and 48 wk for GT ¼	52	25	72	44	41	181
Fuster et al[53] (2006)	Spain Multi Center	110	PEG-IFN 180 μg/wk + RBV 800 mg/d	24 wk for GT 2/3 and 48 wk for GT ¼	53	42	68	55	47	33
Righi et al[54] (2008)	Italy	43	PEG-IFN 2a 180 μg/wk or 2b 1.5 μg/kg per week + RBV (10.6 mg/kg per day)	24 wk for GT 3 and 48 wk for GT-1a	51	30		38		24

¹Responses are on intent to treat analysis. ETR: End of treatment response (HCVRNA < 50 copies/mL); SVR: Sustained virologic response (HCVRNA < 50 copies/mL 6 mo after discontinuing treatment); PEG-IFN: Pegylated interferon; RBV-ribavirin; GT: Genotype; tiw: Three times a week; ACTG: AIDS clinical trial group; APRICOT: AIDS pegasys ribavirin international coinfection trial.